GPM Announces Investigation of Sunesis Pharmaceuticals, Inc.

LOS ANGELES--()--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of Sunesis Pharmaceuticals, Inc. ("Sunesis" or the "Company") (NASDAQ: SNSS). The investigation concerns whether the Company violated specific sections of the Securities Exchange Act of 1934 by issuing materially misleading information to the investing public. Investors who have lost over $50,000 on their Sunesis investment are encouraged to contact GPM to discuss their legal rights.

On July 23, 2015, Sunesis announced that the United States Food and Drug Administration will not approve its blood cancer drug Qinprezo based on available data, and that the Company must provide more clinical evidence supporting approval of Qinprezo. On this news, shares of Sunesis fell $2.25 per share, or more than 70%, during intraday trading on July 24, 2015. Investors have been damaged by the alleged fraud of the Company and GPM is preparing a complaint to seek compensation on behalf of investors.

If you purchased Sunesis shares, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Casey Sadler, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

Release Summary

GPM announces investigation of Sunesis Pharmaceuticals, Inc.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Casey Sadler, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com